Fayez Shamieh, MD
Neurology · Lake Charles, LANPI 1861582504
Payments from drug & device makers
Across 76 payments — averaging $14.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sunovion Pharmaceuticals Inc.$272
- AbbVie$217
- Amgen$125
- Teva Pharmaceuticals USA, Inc.$68
- Supernus Pharmaceuticals, Inc.$56
- Pfizer$53
- plus $278 from 14 others
What the payments were for
- Food & beverage$1,069100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sunovion Pharmaceuticals Inc. | 37 | $272 |
| AbbVie(2 entities) | 12 | $217 |
| Amgen | 1 | $125 |
| Teva Pharmaceuticals USA, Inc. | 4 | $68 |
| Supernus Pharmaceuticals, Inc. | 3 | $56 |
| Pfizer | 3 | $53 |
| AstraZeneca | 2 | $42 |
| Lundbeck LLC | 2 | $36 |
| Life Molecular Imaging Ltd | 1 | $26 |
| Boston Scientific | 1 | $21 |
| Catalyst Pharmaceuticals, Inc. | 1 | $20 |
| Novartis | 1 | $18 |
| Cycle Pharmaceuticals Inc | 1 | $17 |
| Neurocrine Biosciences, Inc. | 1 | $17 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $17 |
| Biogen | 1 | $15 |
| Eisai Inc. | 1 | $15 |
| UCB, Inc. | 1 | $14 |
| Adamas Pharmaceuticals, Inc. | 1 | $12 |
| Insightec,inc | 1 | $7 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- AIMOVIG$125
How this compares
$1,069 in reported general payments places this provider in the 30th percentile of 225 neurology providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| GammakedImmune Globul G/Gly/Iga Avg 46 | 13 | $1,068,172 |
| Gamunex-CImmune Globul G/Gly/Iga Avg 46 | 64 | $869,039 |
| SkyclarysOmaveloxolone | 12 | $389,477 |
| FirdapseAmifampridine Phosphate | 11 | $323,097 |
| OctagamImmun Globg(Igg)/Malt/Iga Ov50 | 26 | $311,956 |
| PrivigenImmun Glob G(Igg)/Pro/Iga 0-50 | 25 | $299,946 |
| TecfideraDimethyl Fumarate | 17 | $160,563 |
| Dimethyl Fumarate | 28 | $130,986 |
| Aimovig AutoinjectorErenumab-Aooe | 32 | $24,275 |
| LamictalLamotrigine | 11 | $17,042 |
| NamzaricMemantine Hcl/Donepezil Hcl | 16 | $12,150 |
| DilantinPhenytoin Sodium Extended | 12 | $5,418 |
| Gabapentin | 272 | $4,297 |
| Levetiracetam | 119 | $3,723 |
| Lacosamide | 51 | $3,274 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| BiogenSkyclarys, Tecfidera | $15 | $550,03929 claims |
| Catalyst Pharmaceuticals, Inc.Firdapse | $20 | $323,09711 claims |
| PfizerOctagam, Dilantin | $53 | $317,37438 claims |
| AbbVieNamzaric | $217 | $12,15016 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 225 neurology providers in Louisiana.
Other neurology in Lake Charles
- Ariel Antezana AntezanaAlexandria$2.5M
- Jon OlsonBaton Rouge$1.7M
- Bridget BagertNew Orleans$1.4M
- Carol RedillasChalmette$1.3M
- Joseph TarsiaNew Orleans$1.2M
- Angela TraylorNew Orleans$941K
- Meghan HarrisShreveport$698K
- Maria Carmen WilsonCovington$681K
- Kevin CallerameBaton Rouge$420K
- Gerald CaleganBaton Rouge$400K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.